SCHEMBL210766

SCHEMBL210766

Clc1nccc(-c2ccc(OCCN3CCOCC3)cc2)n1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.57
RAB9A P51151 1/20 0.57
ACHE P22303 2/20 0.55
BCHE P06276 1/20 0.55
MAOA P21397 1/20 0.55
MAOB P27338 1/20 0.55
KDM4E B2RXH2 1/20 0.54
ALDH1A1 P00352 1/20 0.54
KMO O15229 2/20 0.53
MET P08581 1/20 0.52
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
TBK1 Q9UHD2 1/20 0.51
LTA4H P09960 2/20 0.50
HRH3 Q9Y5N1 1/20 0.50
TGFBR1 P36897 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210965 0.81 HRH3 (0.59) NPC1RAB9AALDH1A1HRH3TGFBR1
SCHEMBL28446714 0.76 JAK2 (0.55) NPC1RAB9AKDM4E
SCHEMBL5282051 0.76 ACHE (0.61) NPC1RAB9AACHEBCHEMAOA
SCHEMBL20745905 0.75 NPC1 (0.56) NPC1RAB9AACHEBCHEMAOA
SCHEMBL25002934 0.74 CYP2D6 (0.59) NPC1RAB9AKDM4EALDH1A1CYP1A2
SCHEMBL11898739 0.74 NPC1 (0.97) NPC1RAB9ALTA4HHRH3
SCHEMBL3398552 0.74 CYP2D6 (0.51) NPC1RAB9AKDM4EALDH1A1CYP1A2
SCHEMBL19560190 0.74 LTA4H (0.67) NPC1RAB9AKDM4EALDH1A1CYP1A2
SCHEMBL15260226 0.74 KDM4E (0.66) NPC1RAB9AMAOAKDM4EALDH1A1
SCHEMBL1221099 0.74 NPC1 (0.55) NPC1RAB9AACHEBCHEMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-20050245518-A1 Antiproliferative agents METHYLGENE, INC. 2005-11-03 US disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 NPC1 1293/4885RAB9A 3036/4885ACHE 3428/4885
US-20050245518-A1 Antiproliferative agents HDAC1, HDAC11, HDAC5 NPC1 1178/4885RAB9A 3239/4885ACHE 3542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.